Skip to main content
SpringerLink
Log in

Dabigatran and rivaroxaban prescription for atrial fibrillation in Catalonia, Spain: the need to manage the introduction of new drugs

  • Letter to the Editors
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Olgren J, Parekh A, RE-LY Steering Committee and Investigators et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151

    Article  CAS  PubMed  Google Scholar 

  2. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891

    Article  CAS  PubMed  Google Scholar 

  3. European Medicines Agency. Pradaxa® (Dabigatran etexilate) product information 26/07/2012. Pradaxa–EMEA/H/C/000829 -II/0032. Available at: http://www.emea.europa.eu/ema/

  4. Harper P, Young L, Merriman E (2012) Bleeding risk with dabigatran in the frail elderly. N Engl J Med 366:864–866

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut Català de la Salut, Barcelona, Catalonia, Spain

    Amelia Troncoso & Eduard Diogène

Authors
  1. Amelia Troncoso
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eduard Diogène
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amelia Troncoso.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Troncoso, A., Diogène, E. Dabigatran and rivaroxaban prescription for atrial fibrillation in Catalonia, Spain: the need to manage the introduction of new drugs. Eur J Clin Pharmacol 70, 249–250 (2014). https://doi.org/10.1007/s00228-013-1593-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-013-1593-6

Keywords

Search

Navigation